| Amy Snodgrass, LPC | |
|
125 Wellness Way, Hot Springs, AR 71913-6478 | |
| (501) 624-7111 | |
| Not Available |
| Full Name | Amy Snodgrass |
|---|---|
| Gender | Female |
| Speciality | Counselor - Mental Health |
| Location | 125 Wellness Way, Hot Springs, Arkansas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073977203 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | P2203008 (Arkansas) | Primary |
| Entity Name | Ouachita Regional Counseling & Mental Health Center, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821087123 PECOS PAC ID: 7416853445 Enrollment ID: O20031210000795 |
News Archive
Researchers at the University of Rochester Medical Center have coined a simple formula that predicts how well a certain chemotherapy will work for targeting brain and other nervous system cancers. The formula, which publishes mid-July in Cancer Chemotherapy and Pharmacology, is pegged to two important proteins that compose such hard-to-kill tumors - one of which, ironically, makes them so drug-resistant in the first place.
The diabetes population in the United States will almost double over the next 25 years and annual medical spending on the disease is projected to hit $336 billion, up from $113 billion today, according to a study published in the December issue of Diabetes Care. The National Changing Diabetes® Program (NCDP), a program of Novo Nordisk, commissioned the analysis by a team from the University of Chicago.
A Houston Methodist-led team of international scientists has identified hundreds of possible new genes in mice that could transform benign skin growths into deadly melanomas.
EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amy Snodgrass, LPC 125 Wellness Way, Hot Springs, AR 71913-6478 Ph: (501) 624-7111 | Amy Snodgrass, LPC 125 Wellness Way, Hot Springs, AR 71913-6478 Ph: (501) 624-7111 |
News Archive
Researchers at the University of Rochester Medical Center have coined a simple formula that predicts how well a certain chemotherapy will work for targeting brain and other nervous system cancers. The formula, which publishes mid-July in Cancer Chemotherapy and Pharmacology, is pegged to two important proteins that compose such hard-to-kill tumors - one of which, ironically, makes them so drug-resistant in the first place.
The diabetes population in the United States will almost double over the next 25 years and annual medical spending on the disease is projected to hit $336 billion, up from $113 billion today, according to a study published in the December issue of Diabetes Care. The National Changing Diabetes® Program (NCDP), a program of Novo Nordisk, commissioned the analysis by a team from the University of Chicago.
A Houston Methodist-led team of international scientists has identified hundreds of possible new genes in mice that could transform benign skin growths into deadly melanomas.
EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor.
› Verified 3 days ago
Mrs. Penny J Almond, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 1401 Malvern Ave, Suite 40, Hot Springs, AR 71901 Phone: 501-538-9360 | |
Rebecca Seel, Counselor Medicare: Not Enrolled in Medicare Practice Location: 1820 Central Ave, Hot Springs, AR 71901 Phone: 501-609-0400 Fax: 501-609-0166 | |
Anna Mccoy, MHPP Counselor Medicare: Not Enrolled in Medicare Practice Location: 225 Mcauley Ct, Suite B, Hot Springs, AR 71913 Phone: 501-321-1779 Fax: 501-321-9078 | |
Cheryl Kuhn, LPC Counselor Medicare: Medicare Enrolled Practice Location: 1820 Central Ave. Ste. B, Hot Springs, AR 71901 Phone: 501-623-6000 Fax: 501-623-6004 | |
Kylie Walton, LAC Counselor Medicare: Not Enrolled in Medicare Practice Location: 3604 Central Ave, Suite C, Hot Springs, AR 71913 Phone: 501-623-9220 Fax: 501-623-9227 | |
Stephanie Hamilton, Counselor Medicare: Medicare Enrolled Practice Location: 1820 Central Ave Ste B, Hot Springs, AR 71901 Phone: 501-623-6000 Fax: 501-623-6004 | |
Ms. Amy Lynn Higdon, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 125 Dons Way, Hot Springs, AR 71913 Phone: 501-624-7111 Fax: 501-620-5109 |